Intravenous solutions for a derivative of staurosporine
US5658898A · kind A · utility
38Cited by
2References
7Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 7, 1995 |
| Grant date | Aug 19, 1997 |
| Priority date | — |
| Expiry date | Nov 7, 2015 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K9/127
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention relates to a novel advantageous dosage form for sparingly soluble staurosporin derivatives, especially N-benzoyl-staurosporin. The dosage form is administrable intravenously in the form of a nanoemulsion and comprises as solubilisers a combination of phospholipids, triglycerides and partial fatty acid esters of polyoxyethylene sorbitan.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.